

## PATENT CLAIMS

1. Use of an  $\alpha v$ - integrin antagonist for the manufacture of a medicament for the  
5 treatment of pathological conditions in a mammal in which activated fibroblast or  
myofibroblasts are involved.
2. Use according to claim 1, wherein the  $\alpha v$ -integrin antagonist is an  $\alpha v\beta 3$   
antagonist.
- 10 3. Use according to claim 1, wherein the  $\alpha v$ -integrin antagonist is an  $\alpha v\beta 6$   
antagonist.
4. Use of claim 2 or 3, wherein the the  $\alpha v$ -integrin antagonist is selected from the  
15 group consisting of  
(i) 3-Benzo [1, 2, 5] thiadiazol-5-yl-3-{6-[2-(6-methylamino-  
pyridin-2-yl)-ethoxy]-1H-indol-3-yl}-propionic acid,  
and  
(ii) 3-{3-Benzylloxy-2-[5-(pyridin-2-ylamino)-  
20 pentanoylamino]-propanoylamino}-3-(3,5-dichloro-  
phenyl)-propionic acid.
5. Use according to any of the claims 1 – 4, wherein the pathological condition is  
fibrosis or a fibrotic disease.
- 25 6. Use according to claim 5, wherein the fibrosis is a fibrotic liver disease.
7. Use according to claim 6, wherein said fibrotic liver disease is liver cirrhosis.
- 30 8. Use according to claim 5, wherein said antagonist inhibits PDGF-induced  
HSC/MF migration and / or activation.
9. Use according to claim 5, wherein said antagonist inhibits scarring.